Jilin Zixin Pharmaceutical

Jilin Zixin Pharmaceutical is a China-based pharmaceutical enterprise that traditionally focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) and ginseng-related products. The company gained international attention for its strategic expansion into high-throughput gene sequencing, developing domestic DNA sequencing platforms like the BIG-isPlex in collaboration with the Chinese Academy of Sciences. However, following years of financial instability and internal management issues, the company faced severe debt crises and was officially delisted from the Shenzhen Stock Exchange in 2023. Its product portfolio includes treatments for cardiovascular, digestive, and respiratory ailments, alongside a large-scale industrial hemp business, though many operations have been disrupted by bankruptcy reorganization proceedings.